MX2023011110A - Terapias de celulas inmunitarias multifuncionales. - Google Patents
Terapias de celulas inmunitarias multifuncionales.Info
- Publication number
- MX2023011110A MX2023011110A MX2023011110A MX2023011110A MX2023011110A MX 2023011110 A MX2023011110 A MX 2023011110A MX 2023011110 A MX2023011110 A MX 2023011110A MX 2023011110 A MX2023011110 A MX 2023011110A MX 2023011110 A MX2023011110 A MX 2023011110A
- Authority
- MX
- Mexico
- Prior art keywords
- car
- adapter
- car cell
- immune cell
- cell therapies
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente se proporcionan composiciones basadas en receptores de antígenos quiméricos (CAR) multifuncionales y su uso para dirigir respuestas inmunitarias a células diana. Las composiciones tienen usos que incluyen el tratamiento de trastornos hiperproliferativos tal como el cáncer. Los métodos proporcionados incluyen en general el uso de una célula CAR en combinación con un Adaptador. El Adaptador confiere la capacidad de modular, alterar y/o redirigir la respuesta inmune mediada por células CAR in vitro e in vivo. En algunas modalidades, la célula CAR comprende una modificación genética para reducir o eliminar la expresión de un determinante antigénico buscado como diana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166550P | 2021-03-26 | 2021-03-26 | |
| PCT/US2022/021633 WO2022204340A1 (en) | 2021-03-26 | 2022-03-24 | Multifunctional immune cell therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011110A true MX2023011110A (es) | 2023-11-23 |
Family
ID=83396077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011110A MX2023011110A (es) | 2021-03-26 | 2022-03-24 | Terapias de celulas inmunitarias multifuncionales. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4313083A1 (es) |
| JP (1) | JP2024512590A (es) |
| KR (1) | KR20230162957A (es) |
| CN (1) | CN117425484A (es) |
| AU (1) | AU2022242842A1 (es) |
| BR (1) | BR112023019689A2 (es) |
| CA (1) | CA3212948A1 (es) |
| IL (1) | IL306096A (es) |
| MX (1) | MX2023011110A (es) |
| WO (1) | WO2022204340A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202003168WA (en) | 2017-11-14 | 2020-05-28 | Arcellx Inc | Multifunctional immune cell therapies |
| US11827716B2 (en) | 2021-11-15 | 2023-11-28 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7285267B2 (ja) * | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Ｄドメイン含有ポリペプチドおよびその使用 |
| SG11202003168WA (en) * | 2017-11-14 | 2020-05-28 | Arcellx Inc | Multifunctional immune cell therapies |
-
2022
- 2022-03-24 CN CN202280037802.2A patent/CN117425484A/zh active Pending
- 2022-03-24 JP JP2023558745A patent/JP2024512590A/ja active Pending
- 2022-03-24 IL IL306096A patent/IL306096A/en unknown
- 2022-03-24 AU AU2022242842A patent/AU2022242842A1/en active Pending
- 2022-03-24 MX MX2023011110A patent/MX2023011110A/es unknown
- 2022-03-24 CA CA3212948A patent/CA3212948A1/en active Pending
- 2022-03-24 BR BR112023019689A patent/BR112023019689A2/pt unknown
- 2022-03-24 KR KR1020237036708A patent/KR20230162957A/ko unknown
- 2022-03-24 EP EP22776612.8A patent/EP4313083A1/en active Pending
- 2022-03-24 WO PCT/US2022/021633 patent/WO2022204340A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3212948A1 (en) | 2022-09-29 |
| IL306096A (en) | 2023-11-01 |
| BR112023019689A2 (pt) | 2023-10-31 |
| AU2022242842A1 (en) | 2023-10-05 |
| CN117425484A (zh) | 2024-01-19 |
| EP4313083A1 (en) | 2024-02-07 |
| KR20230162957A (ko) | 2023-11-29 |
| JP2024512590A (ja) | 2024-03-19 |
| WO2022204340A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550242A1 (en) | Multifunctional immune cell therapies | |
| MX2023011110A (es) | Terapias de celulas inmunitarias multifuncionales. | |
| MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
| KR102592781B1 (ko) | 방사선 치료와 조합된 ｐｄ-1 및 ｐｄ-ｌ1에 대한 길항제를 이용하는 암 치료 방법 | |
| PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| GEP20166442B (en) | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof | |
| MX2019011475A (es) | Celulas inmunes universales manipuladas para ser dotadas con receptor de antigeno quimerico anti-cd22. | |
| MX2021009357A (es) | Dianas de genes de combinacion para mejorar la inmunoterapia. | |
| MX2020009463A (es) | Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor. | |
| MY169644A (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| ES2946332T3 (es) | Un ARNg dirigido a HPK1 y un método para editar el gen HPK1 | |
| MX2020007338A (es) | Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. | |
| MX2020007281A (es) | Composiciones y métodos que se dirigen a cánceres que expresan cd99. | |
| MX2020009475A (es) | Inmunoterapia con celulas car de anticuerpos biespecificos. | |
| EP2552483A4 (en) | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS | |
| MX2020000686A (es) | Composiciones y métodos para el direccionamiento de cánceres que expresan cd33. | |
| MX2022000922A (es) | Celulas inmunes defectuosas para suv39h1. | |
| BR112021021608A2 (pt) | Células car-t direcionadas a cd19 específicas para antígeno | |
| MX2011007307A (es) | Vector de expresion estable contitutivamente alto para preparar vacuna vph y bacteria acido lactica recombinante transformada del mismo modo. | |
| Kumai et al. | Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor | |
| WO2022146891A3 (en) | Methods and compositions for modulating car-t activity | |
| CL2022001715A1 (es) | Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos | |
| MX2022007833A (es) | Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos. | |
| MX2022005816A (es) | Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70. | |
| MX2021013359A (es) | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |